


REFERENCIAMIENTO LEUCEMIA LINFOCÍTICA CRÓNICA

Criterios de Referencia de pacientes con sospecha de cáncer pulmón



LOS RESULTADOS DE LAS PRUEBAS DE **SANGRE, GENÉTICAS Y MOLECULAR** PUEDEN DETERMINAR LA RAPIDEZ CON LA QUE PROGRESARÁ LA ENFERMEDAD Y PUEDEN AYUDAR A DETERMINAR LAS OPCIONES DE TRATAMIENTO. ¹



Por lo general, no se requiere un aspirado de médula ósea ni una biopsia de médula ósea para diagnosticar la LLC.¹ La hibridación in situ fluorescente (FISH) y la citogenética convencional pueden ayudar a distinguir la CLL de otras enfermedades linfoproliferativas.¹

Referencias: 1. Hallek M, et al. Blood. 2018 Mar 14 [Epub ahead of print]. 2. Rigolin GM, Formigaro L, Cavallari M, et al. An extensive molecular cytogenetic characterization in high-risk chronic lymphocytic leukemia identifies karyotype aberrations and TP53 disruption as predictors of outcome and chemo refractoriness. Oncotarget.2017;8(17):28008-28020. 3. Rai KR, et al. Blood. 1975;46:219-234. 4. Rai KR. Chronic lymphocytic leukemia. In: Kufe DW, Pollock MD, Weichselbaum RR, et al, eds. Cancer Medicine. 6th ed. Hamilton, Ontario: BC Decker Inc.; 2003:8-70 5. Norin S, Kimby E. Chronic lymphocytic leukaemia/small lymphocytic lymphoma. In: Ghielmini M, Montoto S, eds. Lymphomas Essentials for Clinicians. 2nd ed. Switzerland: ESMO Press; 2015:43-48. 6. Rai KR, et al. Blood. 1975;46:219-234. 7. Binet J, et al. Cancer. 1981;48:198-206. 14. International CLL-IPI working group. An international prognostic index for patients with chronic lymphocytic leukaemia (CLL-IPI): a meta-analysis of individual patient data. Lancet Oncol. 2016;17(6):779-790. 15. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma. V.2.2020. © 2019 National Comprehensive Cancer Network, Inc. All rights reserved. Accessed October 8, 2019. To view the most recent and complete version of the guideline, go online to NCCN.org. 16. Campo E, Cymbalista F, Ghia P, et al. TP53 aberrations in chronic lymphocytic leukemia: an overview of the clinical implications of improved diagnostics. Haematologica. 2018;103(12):1956-1968. 19. Puiggros A, Collado R, Calasanz MJ, et al. Patients with chronic lymphocytic leukemia and complex karyotype show an adverse outcome even in absence of TP53/ATM FISH deletions. Oncotarget. 2017;8(33):54297-54303. 20. Eichhorst B, Fink A-M, Bahlo J, et al ; for an international group of investigators and the German CLL Study Group (GCLLSG). First-line chemoimmunotherapy with bendamustine and rituximab versus udarabine, cyclophosphamide, and rituximab in patients with advanced chronic lymphocytic leukaemia (CLL10): an international, open-label, randomised, phase 3, non-inferiority trial. Lancet Oncol. 2016;17(7):928-942. 21. Hallek M, Fischer K, Fingerle-Rowson G, et al ; for an international group of investigators and the German Chronic Lymphocytic Leukaemia Study Group. Addition of rituximab to udarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial. Lancet. 2010;376 (9747):1164-1174.

Realizado por AstraZeneca CAMCAR Costa Rica S.A. Roble Corporate Center, 5to piso, Escazú, San José, Costa Rica, teléfono: (506) 2201 3400, apartado postal: 993-1260 Escazú. www.camcar.astrazeneca.com para AstraZeneca CAMCAR S.A. Para reporte de eventos adversos, quejas de calidad o información médica, visite https://www.contactazmedical.astrazeneca.com. Material Exclusivo para profesionales de la salud. CC-11116 / OCTUBRE 2025